🥼Business Ethics in Biotechnology Unit 2 – Ethical Theories in Business Ethics
Ethical theories in business ethics provide frameworks for analyzing complex moral dilemmas in the corporate world. These theories, including utilitarianism, deontology, and virtue ethics, offer different perspectives on how to determine right and wrong actions in business contexts.
The study of ethical theories in business ethics explores their historical development, key principles, and practical applications. By examining case studies and real-world examples, students learn to apply these theories to navigate ethical challenges in areas like biotech, where rapid technological advancements raise new moral questions.
Utilitarianism focuses on maximizing overall happiness and well-being for the greatest number of people
Actions are considered morally right if they produce the greatest good for the most people
Challenges arise in defining and measuring happiness, as well as potential neglect of minority interests
Deontology emphasizes adherence to moral duties and rules, regardless of consequences
Kant's Categorical Imperative states that one should act only according to rules that could become universal laws
Criticisms include rigidity and potential conflicts between competing duties
Virtue ethics concentrates on cultivating moral character traits such as compassion, integrity, and courage
Aristotle identified key virtues as the mean between extremes (courage between cowardice and recklessness)
Challenges include defining and prioritizing virtues across diverse cultures and contexts
Care ethics highlights the importance of empathy, compassion, and attentiveness to relationships and responsibilities
Gilligan emphasized an ethics of care in contrast to Kohlberg's justice-based moral development theory
Rights-based theories assert the existence of fundamental human rights that must be respected and protected
Locke argued for natural rights to life, liberty, and property as the foundation for legitimate government
Conflicts can arise between individual rights and societal interests or between competing rights
Social contract theory posits that moral norms derive from an implicit agreement among members of society
Hobbes and Rousseau offered differing accounts of the social contract and the origins of political authority
Critics argue that the social contract is a fiction and question its binding force on individuals
Historical Context
Ancient Greek philosophers such as Socrates, Plato, and Aristotle laid the foundations for Western ethical thought
Socrates emphasized the importance of self-knowledge and critical examination of beliefs
Plato's theory of Forms posited the existence of eternal, unchanging moral ideals
Aristotle developed virtue ethics and the concept of eudaimonia (human flourishing) as the highest good
Medieval Christian thinkers such as Augustine and Aquinas integrated Greek philosophy with biblical teachings
Augustine grappled with the problem of evil and developed the concept of original sin
Aquinas synthesized Aristotelian ethics with Christian theology in his theory of natural law
The Enlightenment brought a renewed focus on reason, individual rights, and social progress
Kant's deontological ethics and Mill's utilitarianism emerged as influential moral frameworks
The Declaration of Independence and the French Declaration of the Rights of Man and of the Citizen reflected Enlightenment ideals
The 20th century saw the rise of applied ethics and the integration of moral philosophy with real-world issues
The Nuremberg trials and the Universal Declaration of Human Rights responded to the atrocities of World War II
Rawls' theory of justice and Nozick's libertarianism offered competing visions of distributive justice
The civil rights, feminist, and environmental movements drew attention to systemic inequalities and the moral status of marginalized groups
Applying Ethics to Biotech
Biotech raises unique ethical challenges due to its potential to alter living organisms and impact human health and well-being
Genetic engineering, cloning, and stem cell research have generated intense moral debates
The development of new drugs and therapies requires careful consideration of risks, benefits, and equitable access
Informed consent is a key ethical principle in biomedical research and treatment
Participants must be fully informed of potential risks and benefits and freely agree to take part
Challenges arise in obtaining meaningful consent from vulnerable populations or those with diminished autonomy
The principle of non-maleficence (do no harm) is central to biomedical ethics
Researchers and clinicians have a duty to minimize risks and avoid causing unnecessary harm
Difficult trade-offs can emerge between individual and societal interests (mandatory vaccination)
Beneficence requires actively promoting the welfare of patients and research participants
Justice demands the fair distribution of the benefits and burdens of biomedical research and healthcare
Disparities in access to healthcare and representation in clinical trials raise concerns about justice
The global distribution of vaccines during the COVID-19 pandemic highlighted issues of international justice
Respect for autonomy underlies the right of individuals to make informed decisions about their own healthcare
Tensions can arise between respecting patient autonomy and promoting public health (quarantine measures)
Privacy and confidentiality are essential in protecting sensitive medical information
The rise of big data and personalized medicine presents new challenges for safeguarding patient privacy
Case Studies and Real-World Examples
The Tuskegee Syphilis Study (1932-1972) involved the unethical withholding of treatment from African American men with syphilis
The study violated principles of informed consent, non-maleficence, and justice
It led to the establishment of the National Commission for the Protection of Human Subjects and the Belmont Report
The development of the first genetically engineered drug, recombinant human insulin, in 1978 raised questions about the safety and regulation of biotechnology
Animal welfare concerns emerged over the use of genetically modified bacteria to produce the insulin
The approval process set precedents for the oversight of genetically engineered products
The cloning of Dolly the sheep in 1996 sparked intense debate over the ethics of cloning and its potential applications to humans
Critics raised concerns about the instrumentalization of life and the psychological impact on cloned individuals
The U.S. banned federal funding for human cloning research, while other countries imposed varying regulations
The Human Genome Project (1990-2003) and the development of CRISPR gene editing technology have raised hopes for treating genetic diseases while also prompting fears of designer babies and genetic discrimination
Somatic gene therapy aims to treat disease in individual patients, while germline gene editing would alter the genes of future generations
The Chinese scientist He Jiankui's creation of genetically edited babies in 2018 was widely condemned as unethical and illegal
The global COVID-19 pandemic has presented numerous ethical challenges, from the allocation of scarce medical resources to the balance between public health measures and individual liberties
Triage protocols for rationing ventilators and ICU beds have relied on utilitarian calculations of maximizing benefits
Lockdowns, mask mandates, and vaccine requirements have tested the limits of government power and generated backlash among some groups
Ethical Dilemmas in Biotech
Balancing risks and benefits is a central challenge in biotech research and development
Gene therapy holds promise for treating genetic disorders but carries risks of unintended consequences and long-term effects
Clinical trials must weigh the potential benefits to participants against the risks of adverse events
Allocating scarce resources such as funding, expertise, and medical treatments raises questions of distributive justice
Orphan drugs for rare diseases may not be profitable for pharmaceutical companies to develop
Developing countries often lack access to essential medicines and healthcare infrastructure
Respecting cultural and religious diversity can conflict with universal ethical principles
Some religious groups object to the use of embryonic stem cells or the genetic modification of organisms
Indigenous communities may have different views on the ownership and use of genetic resources
Navigating the boundary between therapy and enhancement is a growing challenge as biotech advances
Genetic interventions to treat disease may be more widely accepted than those aimed at enhancing human capacities
The use of performance-enhancing drugs in sports raises concerns about fairness and authenticity
Ensuring transparency and accountability is essential for maintaining public trust in biotech
Conflicts of interest can arise when researchers or institutions have financial stakes in the outcomes of their work
Whistleblower protections and independent oversight are important safeguards against misconduct
Anticipating and mitigating unintended consequences is a key responsibility of biotech researchers and policymakers
The release of genetically modified organisms into the environment could have ecological and health impacts
The potential misuse of biotech for bioweapons or other malicious purposes requires proactive risk assessment and management
Stakeholder Analysis
Patients and research participants are primary stakeholders whose rights and welfare must be protected
Informed consent processes should be robust and ongoing, allowing for withdrawal at any time
Special protections are needed for vulnerable populations such as children, prisoners, and the mentally ill
Healthcare providers and researchers have professional obligations to uphold ethical standards and advance scientific knowledge
Codes of ethics such as the Hippocratic Oath and the Declaration of Helsinki provide guidance for medical practice and research
Researchers must balance the pursuit of knowledge with the minimization of risks and respect for persons
Pharmaceutical and biotech companies have financial interests in developing and marketing new products
Intellectual property protections such as patents can incentivize innovation but also limit access to essential medicines
Marketing practices and drug pricing have come under scrutiny for prioritizing profits over patient welfare
Governments and regulatory agencies are responsible for ensuring the safety and efficacy of biotech products and protecting public health
The FDA and EMA oversee the approval and monitoring of drugs and medical devices
Funding agencies such as the NIH and NSF set research priorities and ethical guidelines
Society as a whole has a stake in the responsible development and use of biotechnology
Public engagement and dialogue are essential for building trust and informing policy decisions
Media coverage and popular culture shape public perceptions and attitudes towards biotech
Future generations will be affected by the long-term consequences of today's biotech decisions
The genetic modification of organisms could have irreversible effects on biodiversity and ecosystems
The pursuit of human enhancement could exacerbate social inequalities and raise questions about the nature of humanity
Regulatory Frameworks
The Nuremberg Code (1947) established basic principles for human subjects research, including voluntary consent and minimization of risk
It was developed in response to the unethical medical experiments conducted by Nazi doctors during World War II
The Code laid the foundation for later research ethics guidelines and regulations
The Declaration of Helsinki (1964) is a set of ethical principles for medical research involving human subjects
It emphasizes the primacy of patient welfare, informed consent, and independent ethical review
The Declaration has been revised several times to address emerging issues such as biobanks and data sharing
The Belmont Report (1979) identified three core principles for research ethics: respect for persons, beneficence, and justice
Respect for persons requires acknowledging autonomy and protecting those with diminished autonomy
Beneficence entails maximizing benefits and minimizing risks to research subjects
Justice demands the fair distribution of the benefits and burdens of research
The Common Rule (1991) is a set of U.S. federal regulations governing human subjects research
It mandates institutional review board (IRB) oversight, informed consent, and risk minimization
Revisions in 2018 aimed to modernize the regulations and reduce administrative burdens
The International Council for Harmonisation (ICH) develops guidelines for the conduct of clinical trials and the manufacture of pharmaceuticals
The ICH Good Clinical Practice (GCP) guideline is a global standard for ensuring the safety and rights of trial participants
The ICH also harmonizes technical requirements for drug development and approval across countries
The UNESCO Universal Declaration on Bioethics and Human Rights (2005) sets out fundamental principles for bioethics at the international level
It addresses issues such as human dignity, non-discrimination, and social responsibility
The Declaration is not legally binding but serves as a framework for national laws and policies
Future Challenges and Considerations
The increasing complexity and interdependence of biotech systems will require new approaches to risk assessment and management
The convergence of biotechnology with other fields such as AI, nanotechnology, and neuroscience raises novel ethical and safety concerns
The potential for synergistic or cascading effects calls for a more holistic and anticipatory approach to governance
The globalization of biotech research and development will necessitate greater international cooperation and harmonization of standards
Differences in national laws and cultural values can create challenges for cross-border collaboration and data sharing
The equitable distribution of the benefits and risks of biotech across countries and populations will be a key issue
The democratization of biotech tools and knowledge will empower more individuals and communities to participate in research and innovation
The rise of citizen science, DIY bio, and biohacking communities challenges traditional models of expertise and authority
Ensuring responsible and inclusive innovation will require new forms of public engagement and co-creation
The blurring of boundaries between natural and artificial, human and non-human, will raise profound questions about identity, agency, and moral status
The creation of chimeras, cyborgs, and AI systems with biological components challenges traditional categories and definitions
The legal and ethical frameworks for governing the rights and responsibilities of novel entities will need to evolve
The pursuit of human enhancement and longevity will have far-reaching social, economic, and political implications
The potential for cognitive, physical, and emotional enhancement raises questions about authenticity, equality, and the nature of human flourishing
The extension of the human lifespan could strain healthcare systems, social safety nets, and intergenerational relations
The existential risks and transformative potential of emerging biotechnologies will require ongoing public deliberation and anticipatory governance
The development of gene drives, synthetic biology, and other powerful tools could have irreversible impacts on ecosystems and future generations
Proactive and adaptive approaches to risk management, such as horizon scanning and scenario planning, will be essential for navigating uncertainty and complexity